Categories: COVID-19NewsVaccine

Moderna Announces Update on Investigational RSV Vaccine

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024

Agency has indicated it expects to complete the review by end of May

CAMBRIDGE, MA / ACCESSWIRE / May 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application (BLA) for mRNA-1345, Moderna’s investigational respiratory syncytial virus (RSV) vaccine, by the previously communicated Prescription Drug User Fee Act (PDUFA) date of May 12, 2024. The FDA has informed Moderna that it is working to conclude the review by the end of May 2024.

The FDA has not informed Moderna of any issues related to vaccine safety, efficacy or quality that would prevent the approval of mRNA-1345.

Moderna remains on track for mRNA-1345 to be reviewed at the CDC’s Advisory Committee on Immunization Practices (ACIP) June 26-27, 2024, meeting, which is necessary prior to commercial launch.

“Moderna is very grateful to the FDA for their continued efforts and diligence,” said Stephen Hoge, M.D., President of Moderna. “We look forward to helping the agency complete the review of our application, and to the June ACIP meeting.”

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential approval of the BLA for mRNA-1345 by the FDA, the timing for that approval, and the Company’s expectations regarding the review of mRNA-1345 at the June ACIP meeting. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Chris Ridley
Global Head of Media Relations
+1 617-800-3651
Christopher.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Red Light Holland Announces Completion of Full Psilocybin Extraction Report with PharmAla

Toronto, Ontario--(Newsfile Corp. - June 7, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE:…

1 hour ago

Helix Launches Clinico-Genomic Datasets for Cardiovascular, Metabolic, Immunology and Inflammation Disorders

Rich longitudinal clinical and genomic data through a network of diverse U.S. health systems.SAN MATEO,…

2 hours ago

Novo Integrated Sciences’ Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million

BELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced…

2 hours ago

Klick Health Adds 18 Senior Leaders as 27-Year Double-Digit Growth Spurt Continues

Independent health agency continues to attract industry’s brightest minds; fortifies teams companywide as part of…

2 hours ago

Women Gone Wild: Intuition Edition Book Launch and Tour

New York, New York--(Newsfile Corp. - June 7, 2024) - The much-anticipated second installment of…

2 hours ago

Fiscal Update: Bemax Estimates an Over 70% Revenue Increase

Dallas, Georgia--(Newsfile Corp. - June 7, 2024) - Bemax Inc. (OTC Pink: BMXC), a private…

2 hours ago